Rei Tsang Shiao

Array ( [id] => 20192154 [patent_doc_number] => 20250268864 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-28 [patent_title] => PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME [patent_app_type] => utility [patent_app_number] => 19/206909 [patent_app_country] => US [patent_app_date] => 2025-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17316 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 274 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19206909 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20057317 [patent_doc_number] => 20250195539 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-19 [patent_title] => Testosterone Dodecanoate Compositions and Methods [patent_app_type] => utility [patent_app_number] => 19/059754 [patent_app_country] => US [patent_app_date] => 2025-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17442 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19059754 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20357278 [patent_doc_number] => 12473261 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-18 [patent_title] => Amino acid compositions [patent_app_type] => utility [patent_app_number] => 19/030439 [patent_app_country] => US [patent_app_date] => 2025-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8277 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19030439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20024776 [patent_doc_number] => 20250162998 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-22 [patent_title] => AMINO ACID COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 19/030399 [patent_app_country] => US [patent_app_date] => 2025-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7542 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19030399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20014316 [patent_doc_number] => 20250152538 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-15 [patent_title] => METHOD FOR TREATING A DISORDER [patent_app_type] => utility [patent_app_number] => 19/021386 [patent_app_country] => US [patent_app_date] => 2025-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12186 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19021386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19938833 [patent_doc_number] => 12310946 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-27 [patent_title] => Pharmaceutical composition for oral administration of edaravone and method of administering same [patent_app_type] => utility [patent_app_number] => 18/932667 [patent_app_country] => US [patent_app_date] => 2024-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 4 [patent_no_of_words] => 17302 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 250 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18932667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19947058 [patent_doc_number] => 12318396 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-06-03 [patent_title] => Oral (17-b)-3-oxoandrost-4-en-17-yl tridecanoate therapy [patent_app_type] => utility [patent_app_number] => 18/924252 [patent_app_country] => US [patent_app_date] => 2024-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 22893 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18924252 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19707740 [patent_doc_number] => 20250017882 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-16 [patent_title] => GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATE [patent_app_type] => utility [patent_app_number] => 18/898132 [patent_app_country] => US [patent_app_date] => 2024-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27560 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18898132 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19845161 [patent_doc_number] => 20250090512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-20 [patent_title] => Dosage Regimen [patent_app_type] => utility [patent_app_number] => 18/790828 [patent_app_country] => US [patent_app_date] => 2024-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 82635 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 266 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18790828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19637396 [patent_doc_number] => 12167992 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-17 [patent_title] => Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state [patent_app_type] => utility [patent_app_number] => 18/758358 [patent_app_country] => US [patent_app_date] => 2024-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 17 [patent_no_of_words] => 27619 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18758358 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19637395 [patent_doc_number] => 12167991 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-17 [patent_title] => Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state [patent_app_type] => utility [patent_app_number] => 18/758344 [patent_app_country] => US [patent_app_date] => 2024-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 17 [patent_no_of_words] => 27570 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18758344 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19510484 [patent_doc_number] => 20240342170 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => METHODS OF TREATING FIBROSIS [patent_app_type] => utility [patent_app_number] => 18/755445 [patent_app_country] => US [patent_app_date] => 2024-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7810 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18755445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19743930 [patent_doc_number] => 20250032495 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER [patent_app_type] => utility [patent_app_number] => 18/751014 [patent_app_country] => US [patent_app_date] => 2024-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23531 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18751014 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19477254 [patent_doc_number] => 20240325296 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-03 [patent_title] => ESKETAMINE FOR THE TREATMENT OF DEPRESSION [patent_app_type] => utility [patent_app_number] => 18/680287 [patent_app_country] => US [patent_app_date] => 2024-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 121540 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18680287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19792136 [patent_doc_number] => 12233059 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-25 [patent_title] => Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent [patent_app_type] => utility [patent_app_number] => 18/670637 [patent_app_country] => US [patent_app_date] => 2024-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 31198 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18670637 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19447248 [patent_doc_number] => 20240307378 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => EFFECTIVE TREATMENT OF DEPRESSION IN PATIENTS HAVING IMPAIRED LEARNING AND/OR MEMORY OR CERTAIN EEG CHARACTERISTICS WITH A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT [patent_app_type] => utility [patent_app_number] => 18/670619 [patent_app_country] => US [patent_app_date] => 2024-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31120 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18670619 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19743942 [patent_doc_number] => 20250032507 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => Testosterone Dodecanoate Compositions and Methods [patent_app_type] => utility [patent_app_number] => 18/654926 [patent_app_country] => US [patent_app_date] => 2024-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22637 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18654926 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19387738 [patent_doc_number] => 20240277608 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => ESKETAMINE FOR THE TREATMENT OF DEPRESSION [patent_app_type] => utility [patent_app_number] => 18/643034 [patent_app_country] => US [patent_app_date] => 2024-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 121457 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 194 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18643034 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19622845 [patent_doc_number] => 12161636 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-10 [patent_title] => Method of increasing lifespan in mammals [patent_app_type] => utility [patent_app_number] => 18/621541 [patent_app_country] => US [patent_app_date] => 2024-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 40 [patent_no_of_words] => 29608 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18621541 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19380903 [patent_doc_number] => 20240270773 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => LPXC INHIBITORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/616636 [patent_app_country] => US [patent_app_date] => 2024-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12879 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18616636 [rel_patent_id] =>[rel_patent_doc_number] =>)